These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38702918)

  • 61. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
    Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
    Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects.
    Rebello S; Compain S; Feng A; Hariry S; Dieterich HA; Jarugula V
    J Clin Pharmacol; 2011 Nov; 51(11):1549-60. PubMed ID: 21406600
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
    Choi DH; Chung JH; Choi JS
    Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
    Klein BC; Miceli R; Severt L; McAllister P; Mechtler L; McVige J; Diamond M; Marmura MJ; Guo H; Finnegan M; Trugman JM
    Cephalalgia; 2023 Jan; 43(1):3331024221128250. PubMed ID: 36620892
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
    Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Olkkola KT; Laine K
    Br J Clin Pharmacol; 2010 Jul; 70(1):78-87. PubMed ID: 20642550
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
    Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
    Yin OQ; Tetsuya K; Miller R
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1339-51. PubMed ID: 25168620
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
    Li M; de Graaf IA; van de Steeg E; de Jager MH; Groothuis GM
    Toxicol In Vitro; 2017 Apr; 40():26-33. PubMed ID: 27939799
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
    Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
    Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats.
    Bors LA; Bajza Á; Mándoki M; Tasi BJ; Cserey G; Imre T; Szabó P; Erdő F
    Brain Res Bull; 2020 Jul; 160():65-73. PubMed ID: 32344126
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
    Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
    Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis.
    Hou M; Luo X; He S; Yang X; Zhang Q; Jin M; Zhang P; Li Y; Bi X; Li J; Cheng C; Xue Q; Xing H; Liu Y
    J Headache Pain; 2024 Jul; 25(1):116. PubMed ID: 39030528
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate.
    Mohamed MF; Minocha M; Trueman S; Feng T; Enejosa J; Fisniku O; Othman AA
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):299-306. PubMed ID: 32648334
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl.
    Kharasch ED; Hoffer C; Altuntas TG; Whittington D
    J Clin Pharmacol; 2004 Mar; 44(3):224-33. PubMed ID: 14973303
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
    Singh A; Balasundaram MK
    Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.
    Zahir H; Kobayashi F; Zamora C; Gajee R; Gordon MS; Babiker HM; Wang Q; Greenberg J; Wagner AJ
    J Clin Pharmacol; 2021 Mar; 61(3):298-306. PubMed ID: 32918831
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.
    Malati CY; Robertson SM; Hunt JD; Chairez C; Alfaro RM; Kovacs JA; Penzak SR
    J Clin Pharmacol; 2012 Jun; 52(6):932-9. PubMed ID: 21646440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.